CA2017315A1 - Inhibiteur de l'interleukine i - Google Patents

Inhibiteur de l'interleukine i

Info

Publication number
CA2017315A1
CA2017315A1 CA2017315A CA2017315A CA2017315A1 CA 2017315 A1 CA2017315 A1 CA 2017315A1 CA 2017315 A CA2017315 A CA 2017315A CA 2017315 A CA2017315 A CA 2017315A CA 2017315 A1 CA2017315 A1 CA 2017315A1
Authority
CA
Canada
Prior art keywords
protein
interleukin
inhibitor
directed
immunosuppression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2017315A
Other languages
English (en)
Other versions
CA2017315C (fr
Inventor
Avi Treves
Vivian Barak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadassah Medical Organization
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2017315A1 publication Critical patent/CA2017315A1/fr
Application granted granted Critical
Publication of CA2017315C publication Critical patent/CA2017315C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002017315A 1989-05-19 1990-05-22 Inhibiteur de l'interleukine i Expired - Fee Related CA2017315C (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US35433089A 1989-05-19 1989-05-19
US07/354,330 1989-05-19
US50899990A 1990-04-12 1990-04-12
US07/508,999 1990-04-12
US52527490A 1990-05-17 1990-05-17
US07/525,274 1990-05-17

Publications (2)

Publication Number Publication Date
CA2017315A1 true CA2017315A1 (fr) 1990-11-19
CA2017315C CA2017315C (fr) 2000-07-18

Family

ID=27408176

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002017315A Expired - Fee Related CA2017315C (fr) 1989-05-19 1990-05-22 Inhibiteur de l'interleukine i

Country Status (5)

Country Link
EP (1) EP0398817B1 (fr)
JP (1) JP2863265B2 (fr)
AT (1) ATE125571T1 (fr)
CA (1) CA2017315C (fr)
DE (1) DE69021128T2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
AU649245B2 (en) * 1990-04-02 1994-05-19 Amgen, Inc. Methods for treating interleukin-1 mediated diseases
DE4106570A1 (de) * 1991-03-01 1992-09-03 Max Planck Gesellschaft Neue inhibitoren der endothelzell-proliferation
KR19990044618A (ko) * 1995-09-13 1999-06-25 다케다 야쿠힌 고교 가부시키가이샤 면역억제제
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
CA2454824A1 (fr) * 2001-07-25 2003-02-06 Nuvelo, Inc. Traitement de troubles concernant les cellules immunitaires et les cellules b

Also Published As

Publication number Publication date
JPH03128397A (ja) 1991-05-31
DE69021128T2 (de) 1996-02-29
DE69021128D1 (de) 1995-08-31
CA2017315C (fr) 2000-07-18
ATE125571T1 (de) 1995-08-15
EP0398817B1 (fr) 1995-07-26
EP0398817A1 (fr) 1990-11-22
JP2863265B2 (ja) 1999-03-03

Similar Documents

Publication Publication Date Title
EP0559632A3 (fr)
EP1119362A4 (fr) Methode utilisant des composes de tetracycline afin d'augmenter une production d'interleukine-10
BG91270A (bg) Антивирусно и антибактериално средство и метод за използването му
MX9707732A (es) Compuestos triciclicos utiles en el tratamiento de desordenes proliferativos de celulas.
MY106272A (en) Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants.
PT804252E (pt) Agentes queladores metalicos que contem monoaminas diamidas e tiois
MY121294A (en) Novel hexanoic acid derivatives.
ES8603271A1 (es) Un metodo de producir una composicion de interleuquina-2
ES2074867T3 (es) Derivados de quinazolina para potenciar la actividad antitumoral.
BR9910251A (pt) Estimulação hematopoiética
CA2151604A1 (fr) Application du riluzole dans le traitement de lesions neurologiques liees a des traumatismes
AU1373499A (en) Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f1 to treat peripheral vascular disease
IT8848329A0 (it) Trattamento batterico di conservazione della qualita' del fieno tramite aggiunta di microorganismi del genere bacillus
GB8806892D0 (en) Lactams their synthesis & use in cosmetic compositions
UA29466C2 (uk) Фармацевтична композиція з антипухлинною активністю
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
CA2017315A1 (fr) Inhibiteur de l'interleukine i
MY133125A (en) Novel dihydroxyhexanoic acid derivatives
EP0736600A3 (fr) Utilisation d'une lymphokine à activité suppressive de virus immunodéficient (ISL) pour inhiber la réplication de virus en particulier de rétrovirus
CA2227533A1 (fr) Agents therapeutiques ameliores
EP0373540A3 (fr) Méthode pour purifier des facteurs de croissance protéiques de fibroblastes
MY104070A (en) Cyclopropane derivatives
AU634003B2 (en) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
EP0348290A3 (fr) Monocytes tueurs activés : activité tumoricide et méthode pour leur contrôle
GR3015470T3 (en) Inhibitors of lysyl oxidase.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20040525